1-2 of 2
Yu Jin, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 1127.
https://doi.org/10.1182/blood.V114.22.1127.1127
Published: 2009
Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 337.
https://doi.org/10.1182/blood.V114.22.337.337
Published: 2009